

20th May, 2024

To,

The Manager - Corporate Relationship Dept.

**BSE** Limited

P. J. Towers, Dalal Street

Fort, Mumbai - 400 001

To.

The Manager - Corporate Compliance National Stock Exchange of India Ltd

Exchange Plaza, Plot No.C-1, G Block, BKC, Bandra (E),

Mumbai 400 051

Scrip Code: BSE - 524500

Scrip Code: NSE - KILITCH

Sub: Intimation of the Board Meeting to consider the Financial Results for the quarter and year ended 31st March, 2024

Dear Sir.

Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the meeting of the Board of Directors of the Company will be held on Monday, 27<sup>th</sup> May, 2024 inter-alia to consider and approve the audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended 31<sup>st</sup> March, 2024.

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2<sup>nd</sup> April, 2019 issued by BSE and Circular Reference no. NSE/CML/2019/11 dated 2<sup>nd</sup> April, 2019 issued by NSE and Company's code of conduct for Prevention of Insider Trading, the Trading Window has been closed with effect from 1<sup>st</sup> April, 2024 and will re-open 48 hours after said financial results are disclosed to the Stock Exchanges.

We request you to kindly take the same on record and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For Kilitch Drugs (India) Limited

Mukund Mehta Managing Director







